Drug Profile


Alternative Names: ConXn; Reasanz; Recombinant human relaxin H2; Recombinant relaxin; Relaxin; Relaxin H2; rhRlx; RLX-030; RLX-030A; SUN-Y8002

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Howard Florey Institute
  • Developer Corthera; Genentech; Novartis
  • Class Heart failure therapies; Peptide hormones
  • Mechanism of Action Peptide hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase II Chronic heart failure; Coronary artery disease; Liver cirrhosis; Portal hypertension
  • Discontinued Diffuse scleroderma; Female infertility; Fibrosis; Labour disorders; Labour induction; Peripheral arterial disorders; Preeclampsia; Pulmonary fibrosis; Pulmonary hypertension

Most Recent Events

  • 16 Jun 2017 Novartis terminates phase III trial in Acute heart failure (Adjunctive treatment) in Japan, South Korea, Philippines, Thailand, Taiwan, Malaysia, Hong Kong, China, India, Jordan, Lebanon, based on results from pivotal adult AHF study CRLX030A2301 (NCT02007720)
  • 24 May 2017 Novartis terminates a phase II trial in Acute heart failure (In infants, In children, In adolescents) in the US, Germany, Switzerland and the United Kingdom (NCT02151383)
  • 27 Jan 2017 Novartis prematurely ends the phase III RELAX-AHF-2 trial for Acute heart failure (Adjunctive treatment) in Latvia and Lithuania (IV) before January 2017 (EudraCT2013-001498-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top